Wegovy is classified as a specialty drug by most insurance plans and pharmacy benefit managers. This designation affects how you get the medication, what you pay, and what hoops you may need to jump through before your plan covers it. The retail price of Wegovy sits around $1,349 per month, which alone places it in the cost range that triggers specialty classification.
What Makes a Drug “Specialty”
There is no single, universal definition of a specialty drug. The label generally applies when a medication hits one or more of the following criteria: high cost, specialized handling or storage, complex administration, or use for chronic or complex conditions. Different insurers and pharmacy benefit managers weigh these factors differently, which is why the same drug can be classified as specialty by one plan and non-specialty by another.
Wegovy checks several of these boxes. It requires refrigeration between 36°F and 46°F, it’s an injectable administered weekly by the patient, it treats a chronic condition (obesity or cardiovascular risk reduction), and its list price exceeds $1,000 a month. Any one of these features could push a drug toward specialty status. Together, they make the classification nearly automatic for most payers.
How Specialty Status Affects Your Experience
When a drug is classified as specialty, your insurer typically places it on one of the highest formulary tiers, often Tier 4 or Tier 5. Higher tiers mean higher out-of-pocket costs for you, usually structured as coinsurance (a percentage of the drug’s price) rather than a flat copay. On a plan with 25% coinsurance at a specialty tier, you could owe over $300 per month before any savings programs.
Specialty drugs also tend to come with prior authorization requirements, meaning your insurer must approve the prescription before you can fill it. For Wegovy, the criteria can be extensive. Maryland’s Medicaid program, as one example, requires documented BMI of at least 27 within the past 90 days for cardiovascular indications, along with evidence of conditions like prior heart attack, prior stroke, or symptomatic peripheral artery disease. The prescribing physician may also need to be a specialist or have consulted with one. Weight management indications carry their own set of requirements, and many commercial plans impose similar hurdles.
Some plans historically required Wegovy to be filled through a specialty pharmacy rather than your local retail pharmacy. Specialty pharmacies handle the cold-chain shipping and often provide patient support services, but they can be less convenient. Novo Nordisk has since expanded access so that patients can fill Wegovy prescriptions at retail pharmacies as well, though your specific plan may still route you through a specialty pharmacy depending on its contracts.
Why the Cold-Chain Requirement Matters
Wegovy pens need to be stored in a refrigerator at 36°F to 46°F until use. You can keep a pen at room temperature (up to 86°F) for a maximum of 28 days, but once that window closes, or if the pen has been frozen or exposed to temperatures above 86°F, it must be thrown away. This cold-chain requirement is a meaningful part of the specialty designation because it adds complexity to shipping, stocking, and dispensing. Pharmacies need the infrastructure to keep the medication within its temperature range from warehouse to your hands.
Medical Monitoring While on Wegovy
Specialty drugs often require closer medical oversight than standard prescriptions, and Wegovy fits this pattern. The medication carries established risks of biliary disease, pancreatitis, bowel obstruction, and gastroparesis. Clinicians are expected to maintain a high level of suspicion for these complications in anyone using the drug, particularly if gastrointestinal symptoms go beyond the typical nausea and appetite changes most patients experience during dose escalation.
Patients with heart failure and reduced pumping capacity need particular caution, as some evidence suggests GLP-1 medications could worsen heart failure events and irregular heart rhythms in that group. People with inflammatory bowel disease are generally advised not to start the drug during an active flare. These monitoring requirements reinforce the specialty classification: this isn’t a medication you pick up and take without ongoing clinical attention.
What This Means for Your Costs
The practical impact of Wegovy’s specialty status comes down to money and access. You should expect a prior authorization process that may take days to weeks, potential step therapy requirements (meaning your insurer wants you to try a cheaper option first), and out-of-pocket costs that reflect the drug’s high tier placement. Novo Nordisk offers a savings program that can reduce costs for commercially insured patients, though the terms and maximum benefit vary. Patients on government insurance programs like Medicare or Medicaid are typically ineligible for manufacturer savings cards.
If your plan denies coverage, the denial letter will usually cite the specific clinical criteria you didn’t meet. Your doctor can submit an appeal with additional documentation. Some patients find that resubmitting with more detailed records of weight-related health conditions or prior treatment attempts changes the outcome.
The specialty drug label isn’t just a pharmacy technicality. It shapes every step between your doctor writing the prescription and the pen arriving in your hands, from where you fill it and how it’s shipped to how much you pay each month.